Company news
Entera Bio Ltd. news in 2023
Entera Bio Ltd.'s news releases, calls and decks from 2023, newest first.
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
December 25, 2023
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform
November 28, 2023
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
November 13, 2023
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis
November 8, 2023
Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting
October 15, 2023
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
September 11, 2023
Entera Bio to Participate in Upcoming Investor Conferences
September 4, 2023
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting
August 15, 2023
Entera Bio Announces Q2 2023 Financial Results and Corporate Updates
August 10, 2023
Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
June 6, 2023
Entera Bio Announces Q1 2023 Financial Results and Corporate Updates
May 4, 2023
Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics
May 2, 2023
Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board
April 25, 2023
Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program
April 2, 2023
Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022
March 30, 2023
Entera Bio Regains Compliance with Nasdaq Listing Requirements
March 22, 2023
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
February 14, 2023
Entera Bio to Participate in the SVB Securities Global Biopharma Conference
February 12, 2023
Decks in 2023
- Investor Presentation (March 2023)
Investor deck · 33 slides · March 2023